StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Synthroid (levothyroxine) [legacy through FY21] by Year

Synthroid (levothyroxine) [legacy through FY21] — Worldwide operational (constant-currency) growth YoY (%) (%)

AbbVie Synthroid (levothyroxine) [legacy through FY21]: 1.3% in FY2019, up 1.9 pts from a year earlier. No newer figure appears in the documents we track.

Latest, FY2019
1.3%
Period ended Dec 31, 2019
Change on a year earlier
+1.9 pts
-0.6% in FY2018
History
3 years
Since FY2017
Sources
3
Documents cited below

Where the FY2019 figure comes from

“|| Synthroid | 786 | — | 786 | 1.3 | n/a | n/a | 1.3 | 1.3”

Source: Form 8-K (abbv-20191231xexhibit9.htm, filed 2020-02-07) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSynthroid (levothyroxine) [legacy through FY21] — Worldwide operational (constant-currency) growth YoY (%) (%)Year on yearSource
FY2019Dec 31, 20191.3%+1.9 ptsForm 8-K (abbv-20191231xexhibit9.htm, filed 2020-02-07) ↗
FY2018Dec 31, 2018-0.6%-2.9 ptsForm 8-K (abbv-20181231xexhibit991.htm, filed 2019-01-25) ↗
FY2017Dec 31, 20172.3%–Form 8-K (abbv-20171231xexhibit991.htm, filed 2018-01-26) ↗

Cite this data

StockData. (2026). AbbVie Synthroid (levothyroxine) [legacy through FY21] (%), annual FY2017–FY2019 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/synthroid-ww-op-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.